Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lipocine ( (LPCN) ) has issued an update.
On April 26, 2024, Lipocine Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of its common stock from time to time through the sales agent. On February 26, 2026, the company filed a prospectus supplement covering up to $50 million of common stock to be sold under this arrangement, providing Lipocine with a mechanism to raise additional equity capital as needed.
The most recent analyst rating on (LPCN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
The score is held back primarily by weak financial performance (losses and persistent cash burn despite $0 debt) and limited valuation support (negative P/E, no dividend). These are partly offset by strong recent technical momentum and positive, catalyst-driven corporate events around Phase 3 progress and favorable safety readouts.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company, organized as a U.S. corporation, that issues common stock with a par value of $0.0001 per share. The company accesses capital markets by selling equity from time to time through designated sales agents under structured sales agreements to support its corporate and operational needs.
Average Trading Volume: 145,305
Technical Sentiment Signal: Buy
Current Market Cap: $46.75M
For a thorough assessment of LPCN stock, go to TipRanks’ Stock Analysis page.